immigrating to England does not seem to increase their risk of MS." I submit that the data presented do not speak to the question of the same versus a higher risk among such immigrants. At face value they would indicate only that there are notably fewer such patients admitted to hospital than expected for native Britons. Whether this reflects more than or the same number affected as if they had stayed at home is not definable.

But even the question as to the numbers observed in relation to those expected is not well satisfied here, in my opinion. I really doubt if crossing the Irish Sea alters appreciably one's chances of having MS, and yet only 168 such patients were ascertained while 225 were expected. Whether this represents input bias or an inappropriate expected number (or both) is undefined. If this be so for the Irish, how much more might this be true of the "new Commonwealth" immigrants? (As an aside, for the colonies at least, definition of specific countries incorporated into the New Britannia would have been helpful.)

The use of a 1971 age distribution for 1966 immigrants may well be questioned because of the drastic increase in numbers, there being over twice as many immigrants in 1971 as in 1961. There is a more important aspect to this increase, however. New Commonwealth immigrants to England from Asia numbered 270 000 in 1961 and 618 000 in 1971; from Africa 43 000 and 158 000 respectively. Thus, one would expect that the majority of such immigrants had been in England less than five years. This raises the practical problem of expectations (by age and sex) from 13 years of hospital admissions versus those from five years or so. This is not completely refuted by limitation to "first admissions of newly diagnosed cases." Some correction perhaps should have been employed for person-years of exposure to the chance of admission.

In terms of the disease itself the rapid increase in the population at risk poses yet other and more important problems. Is five years or so a sufficient period to express an increased risk of MS, as must have been the case for more than half the series? Further, is "exposure" from age 50 to 54 or from age 5 to 9 meaningful in terms of MS? Also, can lifetime "exposure" among the British be equated with shorter "exposure" among immigrants? The question of risk of MS in migrant populations gets very involved, being dependent not only on a sufficiency of people who change their residence from one risk area to another but also on their ages at immigration, their length of stay in the new land, and their ages at prevalence day. It is only to this last point that the expectations of Dr Dean and his colleagues are really addressed. Another problem further to confound the issue is the apparent racial predilection for MS, regardless of geography: MS seems the white man's burden.¹

There is evidence from mortality data that moving from low-risk to high-risk MS regions does increase the risk of dying from MS.² Unpublished data from a large series of US veterans with MS versus military controls also support the concept of an increased risk of MS among southern-born who moved north before entry into service. We have also some information to the same effect from an unfortunately small cohort of Vietnamese who moved to France. However, these works too cannot be taken as definitive, and the question of the fate of migrants from low- to high-risk areas in terms of MS, I believe, perhaps still warrants the Scottish verdict of "not proven."

The study of Dr Dean and his colleagues is indeed a formidable one. Certainly the massive deficit of cases found does not seem readily explicable merely by input bias. There may be further gold to be mined therein. One simple approach would be to look only at the numerator data and to compare immigrants from the varying risk area, but according to age at immigration versus age of onset and age and calendar year of London diagnosis plus race. Distributions of the denominator by age and calendar year of immigration, by country, would also be informative.

J F KURTZKE

Department of Neurology and
Community Medicine,
Georgetown University School of
Medicine, and
Neurology Service,
Veterans Administration Hospital,
Washington, DC

¹ Kurtzke, J F, *Acta Neurologica Scandinavica*, 1975, **51**, 137.

² Kurtzke, J F, *et al*, *Neurology*, 1971, **21**, 1186.

* * * As we understand it, the "new Commonwealth" consists of those countries of the old British Empire, too numerous to detail, that have achieved independence since 1945 and have remained within the Commonwealth. —Ed. *BMJ*.

Folate-responsive neuropathy

SIR,—Two challenging propositions are put forth in the article by Drs M Manzoor and J Runcie (15 May, p 1176). They contend that folate deficiency causes a specific neurological disorder "clinically indistinguishable from subacute combined degeneration of the spinal cord" and that folic acid therapy reverses the neuropathy. If proved, then these observations would offer an important opportunity in the management of otherwise intractably disabled patients. Unfortunately, the hypotheses have not been rigorously tested and require more evidence before acceptance.

The 10 patients recorded were considered to be folate deficient on the results of the activity of *Lactobacillus casei* stimulated by their serum. In none was bone marrow aspiration recorded and only five had a macrocytic anaemia. No comment was made about the possible effect of antibacterial therapy on the microbiological assay system. No results are presented for red cell folate assay, and this more reliable test is surely essential if serious disease is to be attributed to chronic folate deficiency.

It could easily be that inadequate nutrition was secondary to the immobility described. If conclusions are to be drawn about the causative role of folate deficiency in severe neuropathy, then a minimum requirement should be estimation of serum and red cell folate activity in a matched group with comparably severe disability of known aetiology, such as Parkinson's disease.

The conclusion that therapy with folic acid lessened the observed neuropathy could be sustained only by a double-blind controlled trial against placebo. It is exceptionally difficult to single out one facet of medical care as being of overriding importance. It would be regrettable if geriatricians influenced by this article relaxed the effort to remobilise patients because of undue reliance on vitamin therapy of unproved benefit.

It hardly needs restating that folic acid

therapy in undiagnosed vitamin B₁₂ deficiency is potentially disastrous.

MALCOLM C BATESON

Department of Medicine,
Ninewells Hospital,
Dundee

* * * We sent a copy of this letter to Drs Manzoor and Runcie, whose reply is printed below. —Ed. *BMJ*.

SIR,—We are grateful to Dr Bateson for his letter. The views contained therein encapsulate those clinical attitudes which we are anxious to challenge. The definition of folate deficiency states is difficult and at present imprecise. The validity of a low serum folate level is not in question, but rather the interpretation of its clinical significance. In a confused patient with red cell macrocytosis and a florid neuropathy, in our view, little clinical acumen is required to decide this. An important rider in patients with very low serum folate values is the effect of recent antibiotic therapy on this. None of our patients were so treated for at least 10 days prior to folate measurement.

The reference to immobility we find puzzling. The neuropathy we described is not a feature of severe, completely immobilising stroke, for example. Furthermore, intensive physiotherapy in our patients in the absence of concurrent folate administration is without value.

There is no place for the superficially attractive double-blind trial of folate against placebo in a neurological disorder which takes many months and possibly some years to develop and during which increasing and perhaps irreparable damage to the nervous system occurs.

We would agree wholeheartedly that the indiscriminate use of folate in obscure neurological disease is indefensible. This danger is completely avoided by measuring the serum B₁₂ and folate levels together and never singly. The use of folate in such circumstances when the serum B₁₂ is known to be normal is quite different and a clinical trial of such is eminently justifiable.

JOHN RUNCIE
MOHINDRA MANZOOR

University Department of
Geriatric Medicine,
Stobhill General Hospital,
Glasgow

Vaginal candidosis

SIR,—In your leading article on this subject (14 February, p 357) it is stated that "there is no evidence that the fungus [*Candida albicans*] develops any resistance to antifungal agents (with the one exception of amphotericin)." As manufacturers of amphotericin we are interested in this last comment since, according to our records and published evidence, we know of no substantiated clinical reports of resistance to the drug.

The early in-vitro studies of Littman *et al*¹ failed to demonstrate resistance to amphotericin in the strains of *C. albicans* tested; and Athar and Winner² tested some 2015 clinical isolates of candida and found none naturally resistant. It was possible to produce in-vitro resistance by numerous passages, but in such cases the degree of pathogenicity was greatly reduced.²⁻⁵ As Hamilton-Miller³ stated as recently as 1974, "Allowing for the well-known